Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
10 participants
INTERVENTIONAL
2025-09-04
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of GB261 in Systemic Sclerosis
NCT07159009
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
NCT06599307
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
NCT05214794
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
NCT01539395
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
NCT02453256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A study of cizutamig in patients with Systemic Sclerosis (Ssc)
Biological: cizutamig
Cizutamig will be dosed according to the protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological: cizutamig
Cizutamig will be dosed according to the protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of SSc according to the 2013 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification criteria
3. Diffuse cutaneous SSc according to the LeRoy criteria
4. Positive for at least 1 SSc-specific parameter as specified in the protocol
5. Disease duration of ≤ 7 years
6. mRSS ≥ 15
7. Inadequate response to therapies defined in the protocol.
Exclusion Criteria
2. Receipt of or inability to discontinue any excluded therapies as specified in the protocol
3. Receipt of live vaccine within 4 weeks prior to Screening
4. Presence of any concomitant autoimmune disease other than the disease being studied
5. Receiving or anticipated to require total parenteral nutrition during the study
6. Active or history of intestinal pseudo-obstruction OR small intestinal bacteria overgrowth
7. Active or history of gastric antral vascular ectasia
8. Active digital ischemia with gangrene OR requiring antibiotics or amputation at Screening or during the study
9. Active or history of scleroderma renal crisis
10. History of progressive multifocal leukoencephalopathy
11. History of primary immunodeficiency or a hereditary deficiency of the complement system
12. Central nervous system (CNS) disease
13. Have presence of 1 or more significant concurrent medical conditions per investigator judgment
14. Have a diagnosis or history of malignant disease within 5 years prior to Screening
15. Inability to comply with contraception requirements as specified in the protocol
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CND106-RUJN -1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.